Serum Institute of India’s Covishield and Bharat BioTech’s Covaxin next in line for emergency use authorization from DCGI


A day after the Pfizer-BioNTech, Serum Institute of India and Bharat BioTech have also submitted an application to the Drugs Controller General of India (DCGI) for emergency use authorization of their vaccines.

Pune-based Serum Institute of India has developed vaccine “Covishield” in collaboration with Oxford and AstraZeneca whereas Hyderabad-based Bharat BioTech has introduced the homegrown vaccine Covaxin developed in association with Indian Council for Medical Research and National Institute of Virology (NIV).  The vaccine of SII-Oxford-AstraZeneca is the first in queue for testing in patients.

SII claimed to have successfully conducted test of Covishield in the United Kingdom, India and Brazil. The Covishield performed very promising results in symptomatic cases, critical Covid-19 cases in particularly.

In a meeting with states, Prime Minister Narendra Modi had said that the vaccines will be ready in a few weeks after approval by regulatory authorities.


Please enter your comment!
Please enter your name here